What guidance did Biofrontera's management provide for the next earnings period?

What is Biofrontera's latest dividend and current dividend yield?

What does Biofrontera do and what are its main business segments?

What were the key takeaways from Biofrontera’s earnings call?

What is the market's earnings forecast for Biofrontera next quarter?

What were the key takeaways from Biofrontera's earnings call?

What factors drove the changes in Biofrontera's revenue and profit?

What is Biofrontera's gross profit margin?

- **Revenue Growth**: Q4 2025 revenue up 36% YoY to $17.1M, FY2025 up 12% to $41.7M.
- **Gross Margin Transformation**: Q4 2025 gross profit 82% vs. 58% prior, targeting 80-85% in 2026.
- **Clinical Breakthroughs**: 
  - sBCC sNDA with 76% histological clearance, PDUFA date Sept 28, 2026.
  - AK extremities Phase III success, acne Phase IIb 58% lesion reduction.
- **Financial Health**: Q4 net income $5.6M, FY2025 cash position $6.4M, on track for 2026 cash flow breakeven.

**【CEO Summary Section】**
- **Record Revenues**: FY2025 revenue of $41.7M (+12% YoY), Q4 revenue $17.1M (+36% YoY), driven by Ameluz sales and pricing adjustments.
- **Strategic Transaction**: Acquired U.S. rights for Ameluz/RhodoLED, replacing 25%-35% transfer pricing with 12%-15% earn-out, improving gross margin to 82% in Q4.
- **Clinical Milestones**: 
  - sBCC: FDA accepted sNDA with PDUFA date Sept 28, 2026; 76% histological clearance vs. 19% placebo.
  - AK Extremities: Phase III met primary endpoint; expanded label filing Q3 2026 for 240cm² fields.
  - Acne: Phase IIb showed 58% reduction in inflammatory lesions; 86% patient satisfaction.
- **Liquidity**: $11M Series C funding, $3M Xepi sale proceeds, $6.4M cash as of Dec 31, 2025.

**【CFO Financial Commentary】**
- **Q4 2025 Financials**: 
  - Revenue: $17.1M (+36% YoY)
  - COGS: -45% YoY to $1.9M (15% of sales vs. 25%-35% prior)
  - Gross Profit: 82% (vs. 58% prior)
  - Net Income: $5.6M (vs. -$1.4M YoY)
  - Adjusted EBITDA: $4.9M (vs. -$1.4M YoY)
- **Full Year 2025**: 
  - Revenue: $41.7M (+12% YoY)
  - COGS: -43% YoY to $10.1M
  - Gross Profit: 74% (vs. 50% prior)
  - Net Loss: -$10.5M (vs. -$17.8M YoY)
  - Adjusted EBITDA: -$10.6M (vs. -$15.3M YoY)
- **2026 Outlook**: Gross margin 80-85%, full earn-out benefit, cash flow breakeven target.

**【Q&A Highlights】**
- **Gross Margin Stability**: CFO confirms 80-85% range from Q1 2026 onward, stable despite product mix fluctuations.

Biofrontera Inc. (BFRI) Q4 2025 Earnings Call Transcript

- **Resilient Revenue Performance**: Flat YTD despite no price increase, Q3 down 22% due to one-time 2024 stockpiling.
- **Strategic Cost Optimization**: 58% cost of sales reduction via royalty agreement, $11M investor financing.
- **Pipeline Momentum**: 750+ RhodoLED lamps installed, FDA expansion for BCC in Q4 2026, acne Phase II data expected early 2026.
- **Liquidity Strengthening**: $3.4M cash + $5.5M new proceeds, targeting 2026 cash flow breakeven.

**【CEO Summary Section】**
- Year-to-date 2025 revenues remained flat compared to 2024 despite no price increase, demonstrating operational resilience.
- Q3 2025 revenue of $7.0 million (-22% YoY) reflects one-time stockpiling ahead of 2024 price hike, with normalization expected in Q4 and full-year growth on track.
- 750 installed RhodoLED lamps support recurring high-margin Ameluz gel sales, with FDA expansion for superficial BCC expected Q4 2026.
- Phase III AK extremities trial completed enrollment, Phase IIb acne trial nearing completion.
- New royalty agreement with Biofrontera AG reduces cost of sales by 58% and delays payments post-sale.
- Sold Xepi license for $3 million upfront, with potential $7 million in milestones, positioning for 2026 cash flow breakeven.

**【CFO Financial Commentary】**
- Q3 2025: 
  - Revenue: $7.0M (-22% YoY)
  - Operating expenses: $13.3M (-5% YoY)
  - Net loss: $6.6M (vs $5.7M YoY)
  - Adjusted EBITDA: -$6.0M (vs -$4.6M YoY)
- YTD 2025: 
  - Revenue: $24.6M (flat YoY)
  - Operating expenses: $40.5M (flat YoY)
  - Net loss: $16.2M (vs $16.4M YoY)
  - Adjusted EBITDA: -$15.7M (vs -$13.9M YoY)
- Cash position strengthened to $3.4M + $2.5M financing + $3M Xepi sale proceeds.
- Transitioning to direct manufacturing to reduce tariffs and improve inventory control.

**【Q&A Highlights】**
- **Price Increase**: Planned before year-end 2025.
- **Pipeline Timelines**: 
  - AK extremities data expected Jan 2026, FDA submission Q2 2026
  - Acne Phase II data concurrent with AK, Phase III contingent on FDA meeting
- **Breakeven Model**: Full-year 2026 breakeven with seasonal quarterly fluctuations, significant Q4 contribution.

Biofrontera Inc. (BFRI) Q3 2025 Earnings Call Transcript

- **Revenue growth accelerates**: Q2 2025 revenue up 15% YoY to $9.0M, driven by 9.5% volume growth and pricing
- **Cost transformation**: Royalty model slashes COGS by 12-13%, with $3.5M savings in H1
- **Pipeline breakthroughs**: FDA submissions for BCC (Q4 2025) and acne (Q4 2025), plus expanded AK label potential
- **Cash position strengthens**: $7.2M cash + $2.5M Q3 inflow supports 2025 expansion
- **Gross margin improvement**: 42% COGS reduction in Q2, with further gains as royalty model scales

**【CEO Summary Section】**
- **Record-breaking Q2 results**: Sold over 50,000 Ameluz tubes in H1 2025, with 40 RhodoLED XL lamps placed in Q2 alone (total 700+ lamps installed). 
- **Strategic restructuring**: Transferred U.S. IP, FDA approvals, and manufacturing to Biofrontera Inc., reducing transfer price from 25-35% to 12-15% royalty. Secured $11M investment to fund transition.
- **Clinical pipeline progress**: 
  - Phase III AK trunk/neck/extremities trial completed enrollment
  - Phase III superficial basal cell carcinoma trial with 1-year follow-up data ready for FDA submission
  - Phase II acne trial nearing data analysis
- **Regulatory milestones**: CMS approved Ameluz for up to 3 tubes per treatment (600 units), expanding reimbursement potential.

**【CFO Financial Commentary】**
- **Q2 2025 Results**: 
  - Revenue: $9.0M (15% YoY growth)
  - Net loss: $5.3M (vs. $0.3M prior year, driven by non-cash warrant valuation)
  - Adjusted EBITDA: -$5.1M (improving from -$4.7M prior year)
- **Cost improvements**: 
  - Cost of goods sold down $1.7M (42% YoY) due to reduced transfer price
  - Royalty model to further lower COGS by ~12-13% annually
- **Balance sheet**: $7.2M cash as of June 2025, with $2.5M expected Q3 inflow
- **Legal expenses**: $3.4M in Q2 (one-time patent defense costs), expected to normalize in Q3+

Biofrontera Inc. (BFRI) Q2 2025 Earnings Conference Call Transcript

- **Revenue Growth**: Q1 2025 revenue up 9% to $8.6M, driven by Ameluz price hikes and new lamp launches.
- **Cost Efficiency**: COGS down 22%, SG&A expenses reduced by $0.6M through team restructuring.
- **Pipeline Momentum**: 3 Phase III trials nearing completion; acne trial data expected Q4.
- **Financial Health**: Net loss halves to $4.2M; EBITDA stabilizes at $4.4M with improved cash flow management.

**【CEO Business Update】**
- Q1 2025 revenue reached $8.6 million, up 9% YoY, driven by Ameluz sales growth and new RhodoLED XL lamp launches.
- Cost optimization achieved: COGS down 22.1% YoY to $3.1 million, SG&A expenses reduced by $0.6 million.
- Key milestones:
  - FDA-approved Ameluz formulation with 18.5 years of patent protection (until 2043).
  - Final patient enrolled in Phase III trial for AK treatment on extremities.
  - Phase III BCC trial completed 1-year follow-up; NDA submission expected Q4 2025.
  - Phase II acne trial nearing completion with data due end-2025.
- EBITDA improved to $4.4 million (from $4.6 million YoY), with gross profit up $1.5 million.

**【CFO Financial Highlights】**
- Revenue growth: +8.7% YoY, driven by 50% price increase on Ameluz and $0.2M XL lamp sales.
- Cost structure: 25% transfer price on Ameluz inventory reduces COGS; R&D expenses up $1.2M due to US clinical trial assumption.
- Net loss narrowed to $4.2M (-60% YoY), with interest expense down due to debt payoff.
- Cash balance $1.8M; inventory stable at $6.5M.

**【Q&A Key Takeaways】**
- Lamp sales: 18 XL units in Q1; original lamp data pending.
- Sales team: Reorganized with junior reps to reduce costs; no material attrition.
- Gross margin: 25% on new Ameluz inventory, but offset by lower-margin lamp sales.
- Reimbursement: No payer pushback on 3-tube indication; all claims approved to date.

Biofrontera Inc. (BFRI) Q1 2025 Earnings Call Transcript

- **Revenue Milestone**: 2024 sales hit $37.3M, up 9.5% YoY, driven by strategic product launches
- **Product Innovation**: RhodoLED XL lamp adoption and 3-tube treatment approval expand addressable market
- **Clinical Progress**: BCC Phase 3 data submission and acne trial enrollment ahead of schedule
- **Cost Efficiency**: 25% transfer pricing cuts COGS, enabling EBITDA improvement
- **Cash Position**: $5.9M cash on hand after $14.8M 2024 financing

**【CEO Business Overview】**
- **Record Sales Growth**: 2024 total revenue reached $37.3 million, up 9.5% YoY, with Q4 revenue of $12.6 million (+18.5% YoY). 
- **Strategic Product Launches**: 
  - 52 RhodoLED XL lamps sold in Q4 alone (100+ since June 2024 launch)
  - FDA approval for up to 3 Ameluz tubes per treatment
  - Expanded label for trunk, neck, and extremity AK treatments
- **Pipeline Progress**: 
  - Phase 3 BCC study data submission expected H2 2025
  - Acne Phase 2 trial nearing completion (116+ patients enrolled)
  - Phase 1 acne PK study underway
- **Cost Efficiency**: Transfer pricing reduced to 25% of parent company costs

**【CFO Financial Highlights】**
- **Revenue Breakdown**: 
  - 2024: $37.3M (+9.5% YoY) driven by +5% price increase and volume growth
  - Q4: $12.6M (+18.5% YoY) with 2% unit growth
- **Profitability**: 
  - Q4 2024: Net loss $1.4M vs. $3.5M YoY improvement
  - Adjusted EBITDA: -$1.4M (vs. -$3.2M YoY)
- **Expense Management**: 
  - SG&A down 13.5% YoY to $54.5M
  - Legal expenses reduced by $3M
  - Marketing spend optimized
- **Balance Sheet**: 
  - Cash: $5.9M (vs. $1.3M YoY)
  - Inventory: $6.6M (down 39% YoY)
  - 2024 financing: $14.8M net proceeds

**【Q&A Key Takeaways】**
- **Ameluz Demand**: 2% unit growth in Q4 despite stable salesforce
- **Acne Trial**: Enrollment ahead of schedule; potential early completion
- **2025 Margins**: Expect improved gross margin from 25% transfer pricing
- **Price Strategy**: 5% price increase in Q4 with no material forward buying

Biofrontera (BFRI)-21 Mar 25-2024 Q4 Earnings call transcript

Biofrontera (BFRI)-15 Aug 24-2024 Q2 Earnings call transcript

Biofrontera (BFRI)-16 May 24-2024 Q1 Earnings call transcript

- **Revenue Milestone**: 19% YoY growth to $34.1 million, fueled by 86% lamp installation surge.
- **Cost Efficiency**: 25% transfer price reduction and $16 million financing enhance margin potential.
- **Product Innovation**: Q2 2024 XL lamp launch and new Ameluz formulation expand treatment options.
- **Clinical Momentum**: Phase III trials progressing, with data expected mid-2024 to 2025.
- **Financial Health**: On track for 2-digit growth and cash flow positivity within 18 months.

**【CEO Summary Section】**
- **Record Revenue Growth**: Achieved $34.1 million in 2023, a 19% year-over-year increase, driven by 123 BF-RhodoLED lamp installations (86% YoY rise).
- **Cost Optimization & Strategy Shift**: Reduced transfer price to 25% for 2024-25, securing $16 million in financing ($8 million received, $8 million expected Q2). Transitioned from sales-focused to marketing and support-driven strategy.
- **Product Launches & Trials**: Q2 2024 launch of XL lamp for larger skin areas; Phase III trials for peripheral AK and tongue/nose AK underway. New Ameluz formulation and PDT patent granted.
- **Clinical Trial Control**: Assumed clinical trial responsibilities from June 2024, balancing cost savings with reduced transfer price impact.

**【CFO Financial Commentary】**
- **Q4 2023 Results**: Revenue $10.6 million (4% YoY growth), net loss $3.5 million, adjusted EBITDA -$3.2 million.
- **Full Year 2023**: Revenue $34.4 million (19% YoY), net loss $20.1 million. Inventory $10.9 million, cash $1.3 million, bridge loan $4 million.
- **Future Outlook**: Expect 2-digit revenue growth and cash flow positivity within 12-18 months, contingent on clinical trial spend.

**【Q&A Highlights】**
- **Clinical Trial Progress**: Acne trial 50-60% enrolled, data mid-2025; BCC trial data mid-2024. Portable lamp expected in 2 years.
- **Sales Force Stability**: 32 reps with turnover below industry average.
- **Growth Targets**: 19-22% CAGR, aligning with historical performance.

**【Closing Remarks】**
- CEO highlighted transformational changes, including financial restructuring and clinical trial control, positioning the company for future growth.

Actual	-40	-25.8	6.4	-1	-2.2	-2.1	-5.6	-7.23	-4.64	4.45	-2.88	-0.05	-0.98	-0.19	-0.47	-0.57	-0.62	0.195
Forecast		-3.6	-3	-6.8	-5.8	-2.2	-3.9	-43.37	-3.785	-1.19	-1.17	-0.77	-0.835	-0.025	-0.215	-0.42	-0.58	0.195
Surprise	0.00%	-616.67%	+313.33%	+85.29%	+62.07%	+4.55%	-43.59%	+83.33%	-22.59%	+473.95%	-146.15%	+93.51%	-17.37%	-660.00%	-118.60%	-35.71%	-6.90%	0.00%

BFRI

BFRI fundamentals

BFRI Q4 2025 Earnings

Earnings Call

You can ask Aime

BFRI

BFRI fundamentals

BFRI Q4 2025 Earnings

Earnings Call

BFRI Earnings Call Summary for Q4/202510:00 AM on Mar 19, 2026

BFRI Earnings Call Summary for Q3/202510:00 AM on Nov 13, 2025

BFRI Earnings Call Summary for Q2/202510:00 AM on Aug 14, 2025

BFRI Earnings Call Summary for Q1/202510:00 AM on May 16, 2025

BFRI Earnings Call Summary for Q4/202410:00 AM on Mar 21, 2025

You can ask Aime